D
David B. Duggan
Researcher at State University of New York Upstate Medical University
Publications - 31
Citations - 2851
David B. Duggan is an academic researcher from State University of New York Upstate Medical University. The author has contributed to research in topics: Chemotherapy & Breast cancer. The author has an hindex of 18, co-authored 31 publications receiving 2778 citations. Previous affiliations of David B. Duggan include Syracuse University.
Papers
More filters
Journal ArticleDOI
Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
I. Craig Henderson,Donald A. Berry,George D. Demetri,Constance Cirrincione,Lori J. Goldstein,Silvana Martino,James N. Ingle,M. Robert Cooper,Daniel F. Hayes,Katherine Tkaczuk,Gini F. Fleming,James F. Holland,David B. Duggan,John T. Carpenter,Emil Frei,Richard L. Schilsky,William C. Wood,Hyman B. Muss,Larry Norton +18 more
TL;DR: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Journal ArticleDOI
Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial
David B. Duggan,Gina R. Petroni,Jeffrey L. Johnson,John H. Glick,Richard I. Fisher,Joseph M. Connors,George P. Canellos,Bruce A. Peterson +7 more
TL;DR: ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin's disease and ABVD should be considered the standard regimen for treatment of advanced Hodgkin’s disease.
Journal ArticleDOI
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
Eric P. Winer,Donald A. Berry,Susan Woolf,David B. Duggan,Alice B. Kornblith,Lyndsay Harris,Richard Alan Michaelson,Jeffrey A. Kirshner,Gini F. Fleming,Michael C. Perry,Mark L. Graham,Stewart A. Sharp,Roger Keresztes,I. Craig Henderson,Clifford A. Hudis,Hyman B. Muss,Larry Norton +16 more
TL;DR: Higher doses of paclitaxel administered as a 3-hour infusion to women with metastatic breast cancer did not improve response rate, survival, or quality of life, but there was a slight improvement in time to progression with higher dose therapy, which was offset by greater toxicity.
Journal ArticleDOI
HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA.
David B. Duggan,Garth D. Ehrlich,Frederick P. Davey,Shirley Kwok,John J. Sninsky,Jack Goldberg,Leon Baltrucki,Bernard J. Poiesz +7 more
TL;DR: It is concluded that the clinical and pathologic diagnosis of HTLV-I-related lymphoma can be difficult and can be confused with Hodgkin's disease.
Journal Article
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Daniel F. Hayes,Hideko Yamauchi,Gloria Broadwater,Constance Cirrincione,Stephen P. Rodrigue,Donald A. Berry,Jerry Younger,Lawrence L. Panasci,Frederick E. Millard,David B. Duggan,Larry Norton,I. Craig Henderson +11 more
TL;DR: ECD/her-2 levels are elevated in 35-40% of patients with metastatic breast cancer and are associated with a poorer prognosis in these patients, but no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.